Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose
Mahesh N Samtani,1 Isaac Nuamah,1 Srihari Gopal,1 Bart Remmerie,2 Jennifer Kern Sliwa,3 Larry Alphs31Janssen Research and Development, LLC, NJ, USA; 2Janssen Research and Development, LLC, Division of Janssen Pharmaceutica NV, Beerse, Belgium; 3Janssen Scientific Affairs, LLC, NJ, USABackground: Pal...
Guardado en:
Autores principales: | Samtani MN, Nuamah I, Gopal S, Remmerie B, Sliwa JK, Alphs L |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/90eb92f46b6142469fd8224a6c3cebc8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
por: Sliwa JK, et al.
Publicado: (2012) -
Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs L, et al.
Publicado: (2013) -
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews M, et al.
Publicado: (2019) -
Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
por: Srihari Gopal, et al.
Publicado: (2011) -
Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study
por: Si TM, et al.
Publicado: (2015)